Case Reports in Medicine / 2013 / Article / Tab 1

Case Report

Primary Spinal Germ Cell Tumors: A Case Analysis and Review of Treatment Paradigms

Table 1

Reported cases of primary spinal germ cell tumors.

Patient no.SeriesCountryAge/sexLocation MedullaryOperationRadiation craniospinal (Gy)Radiation Local (Gy)ChemotherapyHCGSTGCFollowupRecurrence

1Hisa et al. [5]Japan5/MT11-L3IM, EMBx35 + 75Actinomycin + methotrexate + vincristine/bleomycin + cisplatin + vinblastine++6 monthsR, NR after amputation of spinal cord
2Zhu et al. [6]China7/MT12-L1IMPRNDND++
3Slagel et al. [7]Japan16/FT11-L4IM, EMPR3028 monthsNR
4 Aoyama et al. [8]Japan16/FT9-T12IMPR30.6Ifosfamide + cisplatin + etoposide+3 yearsNR
5Chute et al. [9]US18/MT6-T8IMBx50+6 monthsNR
6Huang et al. [10]US18/MC3-C6IMPRNDNDBleomycin + cisplatin + etoposide6 monthsNR
7Kiyuna et al. [11]Japan20/FT11-L3EMTR30.4402 yearsNR
8Massimino et al. [12]Italy20/ML2IMTR309Cisplatin + etoposide + bleomycin++33 monthsNR
9Kinoshita et al. [13]Japan21/FT9-T11, L2-L3IMPR25.2Carboplatin + etoposide3 yearsNR
10Takahashi et al. [14]Japan22/FL1-L2IM, EMPR5730.6Ifosfamide + carboplatin or cisplatin + etoposide+1.5 yearsNR
11Yamagata et al. [15]Japan24/FT6-T7IMPR25.619.8Ifosfamide + cisplatin + etoposide++6 monthsNR
12 Kawano and Tsujimura [16]Japan24/ML1-L3IM, EMPR1640NDNR
13Itoh et al. [17]Japan24/MT11-T12IMTR24.152.113 monthsNR
14Miyauchi et al. [18]Japan24/MT12-L3IM, EMPR154015 monthsNR
15Nakata et al. [19]Japan27/MT7-T9IMPR481 yearR
16Biswas et al. [20]India28/ML2-L4EMTR20Bleomycin + cisplatin + etoposide++11 monthsR
17Tekkök and Sav [21]Turkey28/ML1-S2EMTR5451Cisplatin + etoposide + bleomycin22 monthsR, NR after chemotherapy and reresection
18Ganslandt et al. [22]Germany29/MT12-L4IMTR3218.42 yearsNR
19Matsuoka et al. [23]Japan31/FT12-L2IMPR5015 monthsNR
20Nagasawa et al. [24]Japan31/MMidcervicalIM5140 monthsNR
21Sasaki et al. [25]Japan32/FT3-T4IM27.519.8Methotrexate + etoposide++5 yearsNR
22Watanabe et al. [26] Japan33/FT1-T3IMPR30Carboplatin + etoposideND1 yearNR
23Hata et al. [27]Japan33/MT7-T9IMPR36Carboplatin + etoposide38 monthsNR
24Yamagata et al. [15] Japan33/MT9-T11IMPR24Cisplatin + etoposide2 yearsNR
25Hanafusa et al. [28]Japan34/FT10-T11IMTR304524 monthsNR
26Matsuyama et al. [29]Japan34/FT6-T8IMPR4612 monthsNR
27Aoyama et al. [8]Japan34/FT8-T10IMBx30.6Ifosfamide + cisplatin + etoposide+2 yearsNR
28Nakata et al. [19] Japan35/MT6-T7IMTR24Carboplatin + etoposide+2 yearsNR
29Horvath et al. [30]Japan43/ML1-L2EMTR36148 monthsNR
30Present caseUSA45/MT2-T5IMPR4522 monthsNR

Bx: biopsy; PR: partial resection; TR: total resection; HCG: β-human chorionic gonadotropin; STGC: syncytiotrophoblastic giant cells; M: male; F: female; R: recurrence; NR: norecurrence; bold font: patients with recurrence; IM: intramedullary; EM: extramedullary.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.